|
À¯·´ ±¹°¡(ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹)ÀÇ ºÐÀÚ Áø´Ü ½ÃÀå
Europe Nucleic Acid Testing/NAT Market for 100 Assays: France, Germany, Italy, Spain, UK--Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing
|
¸®¼Ä¡»ç |
Venture Planning Group
|
¹ßÇàÀÏ |
|
»óǰ ÄÚµå |
233420 |
ÆäÀÌÁö Á¤º¸ |
¿µ¹® |
°¡°Ý |
|
À¯·´ ±¹°¡(ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹)ÀÇ ºÐÀÚ Áø´Ü ½ÃÀå
Europe Nucleic Acid Testing/NAT Market for 100 Assays: France, Germany, Italy, Spain, UK--Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing
|
¹ßÇàÀÏ : | ÆäÀÌÁö Á¤º¸ : ¿µ¹® |
|
|
À¯·´ ÁÖ¿ä 5°³±¹(ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹) ºÐÀÚ Áø´Ü(Molecular Diagnostics) ½ÃÀåÀÇ Ãֽе¿Çâ°ú ÇâÈÄ Àü¸Á¿¡ ´ëÇØ ºÐ¼®Çϰí, °Ë»ç ±â¼ú ¿¬±¸°³¹ß Ãֽе¿Çâ, °¢±¹ ½ÃÀå ±âº» ±¸Á¶¿Í µ¿Çâ, ÇâÈÄ 5³â°£ ½ÃÀå µ¿Çâ ¿¹Ãø, ½ÃÀå È®ÀåÀ» À§ÇÑ Àü·«°ú °úÁ¦, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
1. ¼·Ð
2. ¼¼°è ½ÃÀå°ú ±â¼ú °³¿ä
- DNA ½ÃÄö½Ì
- ¼·Ð
- ½ÃÄö½Ì ¹æ¹ý
- ¿ÀÅä¶óµð¿À±×·¡ÇÇ
- Àΰ£°Ô³ð ÇÁ·ÎÁ§Æ®
- ½ÃÄö½Ì ÀÚµ¿È
- À̹ÌÁö ½ºÄ³³Ê
- Çü±¤ °ËÃâ
- À¯ÀüÀÚ ÇÁ·ÎÆÄÀϸµ
- À¯ÀüÀÚ ¹ßÇö
- À¯ÀüÀÚ ´ÙÇü
- ´Ü¹éÁú »óÈ£ÀÛ¿ë ³×Æ®¿öÅ©
- DNA ¹× RNA ÇÁ·Îºê ±â¼ú
- ±âº»Àû ¿øÄ¢
- ÇÁ·Îºê ºÐ¸®
- DNA ÇÁ·Îºê °Ë»ç
- °Ë»ç Æ÷¸Ë
- Ç¥Áö ±â¼ú
- ÁõÆø ¹æ¹ý
- °ËÃâ ±â¼ú
- ¹æ»ç¼±¿¡ ÀÇÇÑ ¹æ¹ý
- Non-Isotopic ¹æ¹ý
- ÀåÄ¡ ¸®ºä
- Abbott LCx
- Beckman Coulter/Biomek FK
- Becton Dickinson SDA
- Bio-Rad GeneScope
- Gen-Probe Tigris
- Roche Cobas Amplicor
- Tecan LS Series
- ¹ÙÀÌ¿ÀĨ : °Ô³ë¼¾¼, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, Labs-on-the-chip
- ¾×ü ¼ö¼Û ¹× È¥ÇÕ
- ºÐ¸®
- ¹ÝÀÀ
- ŽÁö
- ¾à¹°À¯Àüü(Pharmacogenomics)
- ÁÖ¿ä ÀÀ¿ë ºÐ¾ß
- ¹Ì»ý¹°ÇÐ/°¨¿°Áõ
- ¾Ï°Ë»ç
- À¯Àü¼º Áúȯ
- ¹ýÀÇÇÐÀû °Ë»ç
- Ä£ÀÚ °¨Á¤/HLAÇü °áÁ¤
- ±âŸ ÀÀ¿ë ºÐ¾ß
- °æÀï ¹× º¸¿Ï ±â¼ú
- ´ÜÀÏŬ·ÐÇ×ü/¸é¿ªºÐ¼®
- RNA ÇÁ·Îºê
- 2Â÷ Àü±â¿µµ¿
- À¯¼¼Æ÷ºÐ¼®±â(Flow Cytometry)
3. ÇÁ¶û½º ½ÃÀå
- °³¿ä
- »ç¾÷ ȯ°æ
- ½ÃÀå ±¸Á¶
- ½ÃÀå±Ô¸ð, ¼ºÀå·ü, ÁÖ¿ä °ø±Þ¾÷ü ¸ÅÃâ¾× ¹× ½ÃÀå Á¡À¯À²
4. µ¶ÀÏ ½ÃÀå
- °³¿ä
- »ç¾÷ ȯ°æ
- ½ÃÀå ±¸Á¶
- ½ÃÀå±Ô¸ð, ¼ºÀå·ü, ÁÖ¿ä °ø±Þ¾÷ü ¸ÅÃâ¾× ¹× ½ÃÀå Á¡À¯À²
5. ÀÌÅ»¸®¾Æ ½ÃÀå
- °³¿ä
- »ç¾÷ ȯ°æ
- ½ÃÀå ±¸Á¶
- ½ÃÀå±Ô¸ð, ¼ºÀå·ü, ÁÖ¿ä °ø±Þ¾÷ü ¸ÅÃâ¾× ¹× ½ÃÀå Á¡À¯À²
6. ½ºÆäÀÎ ½ÃÀå
- °³¿ä
- »ç¾÷ ȯ°æ
- ½ÃÀå ±¸Á¶
- ½ÃÀå±Ô¸ð, ¼ºÀå·ü, ÁÖ¿ä °ø±Þ¾÷ü ¸ÅÃâ¾× ¹× ½ÃÀå Á¡À¯À²
7. ¿µ±¹ ½ÃÀå
- °³¿ä
- »ç¾÷ ȯ°æ
- ½ÃÀå ±¸Á¶
- ½ÃÀå±Ô¸ð, ¼ºÀå·ü, ÁÖ¿ä °ø±Þ¾÷ü ¸ÅÃâ¾× ¹× ½ÃÀå Á¡À¯À²
8. ÁÖ¿ä Á¦Ç° °³¹ß ±âȸ
- ±â±â
- ½Ã¾à ŰƮ ¹× °Ë»ç ½Ã½ºÅÛ/ÆÐ³Î
- ÄÄÇ»ÅÍ, ¼ÒÇÁÆ®¿þ¾î, ¿ÀÅä¸ÞÀ̼Ç
- º¸Á¶ Á¦Ç°
9. ºÐ»êÇü °Ë»ç Á¦Ç° ¼³°è ±âÁØ
10. ´ëüÀû ½ÃÀå ÁøÃâ Àü·«
- ³»ºÎ °³¹ß
- ÇÕÀÛÅõÀÚ ÇùÁ¤
- ´ëÇаúÀÇ °è¾à
- ºÐ»êÇü °Ë»ç ½ÃÀå À¯Åë Àü·«
- ¸¶ÄÉÆÃ ¹æ¹ý
- Á¦Ç° º¹À⼺
- °í°´ ¼±È£
- ±âÁ¸ °ø±Þ¾÷ü
- ½Å±Ô ÁøÃâ °ø±Þ¾÷ü
- ÁÖ¿ä Á¾·ùÀÇ À¯Åë¾÷ü
- ½ÃÀå ¼¼ºÐÈ
11. ÀáÀçÀû ½ÃÀå ÁøÃâ À庮°ú À§Çè
- ½ÃÀå ¼º¼÷È
- ºñ¿ë ¾ïÁ¦
- °æÀï
- ±â¼ú ÇѰè
- ƯÇã º¸È£
- ±ÔÁ¦¿¡ ÀÇÇÑ ¾ïÁ¦
- ºÐ»êÇü °Ë»ç ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
12. °æÀï»ç °³¿ä
- Abbott
- Affymetrix
- Agilent
- Applied Gene Technologies
- Arca
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- BioMerieux
- Bio-Rad
- Biotest
- Caliper
- Cepheid
- Decode
- Diadexus
- Eiken
- Enzo
- Exact Sciences
- Fujirebio
- Gen-Probe
- Hologic
- Illumina
- Innogenetics/Solvay
- Kreatech
- Li-Cor Biosciences
- Life Technologies
- Monogram Biosciences
- Myriad Genetics
- Nanogen/Elitech
- Novartis
- Orchid CellMark
- Ortho-Clinical Diagnostics
- Proteome Sciences
- Qiagen
- Roche
- Scienion
- Sequenom
- Shimadzu
- Siemens
- Sierra Molecular
- Takara Bio
- Tecan Group
13. ºÎ·Ï
- ºÎ·Ï I : ÁÖ¿ä ´ëÇÐ ¹× ¿¬±¸±â°ü
- ºÎ·Ï II : ¿ë¾îÁý
- ºÎ·Ï III : ÇöÀç ȯÀ²
µµÇ¥
KSM 12.03.22¡Ø ÀÌ ÆäÀÌÁö¿¡ °ÔÀçµÇ¾î ÀÖ´Â ³»¿ëÀº ÃÖ½ÅÆÇ°ú ¾à°£ Â÷À̰¡ ÀÖÀ» ¼ö ÀÖÀ¸¹Ç·Î ¿µ¹®¸ñÂ÷¸¦ ÇÔ²² ÂüÁ¶ÇÏ¿© Áֽñ⠹ٶø´Ï´Ù. ±âŸ ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇ ¹Ù¶ø´Ï´Ù.
This new 1,273-page comprehensive five-country report from VPGMarketResearch is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years. The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years. Table of Contents I. Introduction II. Worldwide Technology and Market Overview A. DNA Sequencing B. DNA and RNA Probes Technology C. Detection technologies D. Instrumentation Review E. Biochips: Genosensors, Microarrays, and Labs-on-the-Chip F. Pharmacogenomics G. Major Applications III. France IV. Germany V. Italy VI. Spain VII. U.K. VIII. Major Product Development Opportunities IX. Design Criteria for Decentralized Testing Products X. Alternative Market Penetration Strategies XI. Potential Market Entry Barriers and Risks XII. Competitive Assessments XIII. Appendix Contains 1,273 pages and 139 tables
Table of Contents
I. Introduction
II. Worldwide Technology and Market Overview
- A. DNA Sequencing
- B. DNA and RNA Probes Technology
- C. Detection Technologies
- D. Instrumentation Review
- E. Biochips: Genosensors, Microarrays, and Labs-on-the-Chip
- F. Pharmacogenomics
- G. Major Applications
III. France
IV. Germany
V. Italy
VI. Spain
VII. U.K.
VIII. Major Product Development Opportunities
IX. Design Criteria for Decentralized Testing Products
X. Alternative Market Penetration Strategies
XI. Potential Market Entry Barriers and Risks
XII. Competitive Assessments
XIII. Appendix
|

|
°¨¿°Áõ ºÐÀÚÁø´Ü °Ë»ç : ¼¼°è ½ÃÀå Á¡À¯À², Àü·«, ¿¹Ãø
¼¼°èÀÇ µ¿¹° Ç¥ÁؽÇÇè½Ç ½ÃÀå ¿¹Ãø(-2024³â) : ÀÓ»óÈÇÐ °Ë»ç(»ýÈÇÐ °Ë»ç), Ç÷¾×°Ë»ç, ¸é¿ªÁø´Ü, ºÐÀÚÁø´Ü
¼¼°èÀÇ ¾Ï ºÐÀÚÁø´Ü ½ÃÀå(2019-2023³â)
¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå ¿¹Ãø(-2025³â)
¼¼°èÀÇ ºÐÀÚÁø´Ü Point of Care(POC) ½ÃÀå - ºÐ¼®°ú ¿¹Ãø : ¾ÖÇø®ÄÉÀ̼Ç, ±â¼ú, Á¾·ù, ÃÖÁ¾»ç¿ëÀÚ, 15°³±¹ µ¥ÀÌÅÍ, °æÀï ±¸µµ(2019-2029³â)
¼¼°èÀÇ POC(Point of Care) ºÐÀÚÁø´Ü ½ÃÀå(±â¼úº°, °¨¿°Áõº°, Áö¿ªº°) : ½ÃÀå ±Ô¸ð, Áö¿ªº° Àü¸Á, »ê¾÷ ºÐ¼®, ¼ºÀå °¡´É¼º, °¡°Ý µ¿Çâ, °æÀï ½ÃÀå Á¡À¯À², ¿¹Ãø
¼¼°èÀÇ µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå ¿¹Ãø(-2024³â) : ¸é¿ªÁø´Ü, ºÐÀÚÁø´Ü, ¼¼±Õ °¨¿°Áõ, ¹ÙÀÌ·¯½º °¨¿°Áõ, ±â»ýÃæ °¨¿°Áõ
¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå : Á¦8ÆÇ(°¨¿°Áõ ºÐÀÚÁø´Ü, Ç÷¾× ½ºÅ©¸®´× ºÐÀÚÁø´Ü, Á¶Á÷/¼¼Æ÷ ºÐÀÚÁø´Ü, ¾Ï ºÐÀÚÁø´Ü, ÀÌ½Ä ºÐÀÚÁø´Ü, À¯Àü¼º Áúȯ ºÐÀÚÁø´Ü)
¼¼°èÀÇ POC(Point of Care) ºÐÀÚÁø´Ü ½ÃÀå : °Ë»çÀå¼Òº°(OTC, PoC), ¿ëµµº°(°¨¿°Áõ, Á¾¾ç), ÃÖÁ¾ ¿ëµµº°, ±â¼úº°, ºÎ¹®º° ¿¹Ãø(2019-2024³â)
ÆÐÇ÷Áõ Áø´Ü ½ÃÀå ±Ô¸ð ºÐ¼® : º´¿øÃ¼º°(¼¼±Õ, Áø±Õ), ±â¼úº°(¹Ì»ý¹°ÇÐ, ºÐÀÚ Áø´Ü, ¸é¿ªÃøÁ¤¹ý), Á¦Ç°º°, °Ë»ç Á¾·ùº°, ºÎ¹®º° ¿¹Ãø(2019-2026³â)
|